ICU Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44930G1076
USD
142.35
-4.31 (-2.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ICU Medical, Inc. stock-summary
stock-summary
ICU Medical, Inc.
Pharmaceuticals & Biotechnology
ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.
Company Coordinates stock-summary
Company Details
951 Calle Amanecer , SAN CLEMENTE CA : 92673
stock-summary
Tel: 1 949 36621831 646 2771254
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 86 Schemes (82.87%)

Foreign Institutions

Held by 122 Foreign Institutions (11.87%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Vivek Jain
Chairman of the Board, Chief Executive Officer
Mr. David Greenberg
Lead Independent Director
Dr. George Lopez
Director
Mr. Donald Abbey
Independent Director
Ms. Elisha Finney
Independent Director
Mr. David Hoffmeister
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
549 Million
(Quarterly Results - Jun 2025)
Net Profit:
35 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,223 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.50

stock-summary
Return on Equity

0.79%

stock-summary
Price to Book

1.52